Elevation Oncology (ELEV) Stock Price, News & Analysis

Company Overview

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $0.37 to $0.37
• 50-Day Range: $0.36 to $0.39
• 52-Week Range: $0.22 to $3.09
• Volume: N/A
• Average Volume: 1.18 million shs
• Market Capitalization: $21.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.62
• Consensus Rating: Hold

ELEV Stock Analysis - Frequently Asked Questions

How were Elevation Oncology's earnings last quarter?

Elevation Oncology, Inc. (NASDAQ:ELEV) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.04.

When did Elevation Oncology IPO?

Elevation Oncology (ELEV) raised $1 billion in an IPO on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

Who are Elevation Oncology's major shareholders?

Top institutional investors of Elevation Oncology include Opaleye Management Inc. (2.44%), Deltec Asset Management LLC (2.43%), Rangeley Capital LLC (1.53%) and Geode Capital Management LLC (0.91%).
View institutional ownership trends.

What other stocks do shareholders of Elevation Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevation Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELEV
• CIK: 1783032
• Web: www.elevationoncology.com
• Phone: 716-371-1125
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Elevation Oncology: $2.62
• High Price Target: $7.00
• Low Price Target: $0.70
• Potential Upside/Downside: +616.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -74.68%
• Return on Assets: -48.14%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 19.40
• Quick Ratio: 19.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.02 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 59,220,000
• Free Float: 54,427,000
• Market Cap: $21.62 million
• Optionable: Optionable
• Beta: 1.48